List of Excipients in API rifapentine
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing rifapentine
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| sanofi-aventis US LLC | PRIFTIN | rifapentine | 0088-2102 | ALUMINUM OXIDE | |
| sanofi-aventis US LLC | PRIFTIN | rifapentine | 0088-2102 | CALCIUM STEARATE | |
| sanofi-aventis US LLC | PRIFTIN | rifapentine | 0088-2102 | CELLULOSE, MICROCRYSTALLINE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for rifapentine
Excipient focus: ALUMINUM OXIDE
rifapentine drug variants containing ALUMINUM OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing ALUMINUM OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CALCIUM STEARATE
rifapentine drug variants containing CALCIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing CALCIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
rifapentine drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
rifapentine drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2
rifapentine drug variants containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
rifapentine drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
rifapentine drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
rifapentine drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
rifapentine drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
rifapentine drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM ASCORBATE
rifapentine drug variants containing SODIUM ASCORBATE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing SODIUM ASCORBATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
rifapentine drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A CORN
rifapentine drug variants containing SODIUM STARCH GLYCOLATE TYPE A CORN
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing SODIUM STARCH GLYCOLATE TYPE A CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STARCH, CORN
rifapentine drug variants containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
rifapentine drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| sanofi-aventis US LLC | rifapentine | 0088-2102 |
| A-S Medication Solutions | rifapentine | 50090-5063 |
| RPK Pharmaceuticals Inc | rifapentine | 53002-1718 |
| >Company | >Ingredient | >NDC |
rifapentine drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
